A Non-interventional Observational Study to Assess Long-term Efficacy and Safety of Dupilumab for the Treatment of Patients (>= 12 Years) With Eosinophilic Esophagitis Under Real-world-conditions in Germany

NCT06695897 · clinicaltrials.gov ↗

RECRUITING

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Eosinophilic Esophagitis

Interventions

DRUG: Dupilumab

Sponsor

Sanofi

Collaborators

Regeneron Pharmaceuticals